DiaSorin SpA (DIA) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

454.62 k

Shareholding (Dec 2023)

FII

0.01%

Held by 2 FIIs

DII

99.99%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of -10.58% and Operating profit at -13.28% over the last 5 years

With ROE of 6.73%, it has a Very Expensive valuation with a 2.71 Price to Book Value

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

EUR 3,426 Million ()

P/E

40.00

Industry P/E

Dividend Yield

1.96%

Debt Equity

0.34

Return on Equity

6.73%

Price to Book

2.23

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2016)

Net Profit:

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-19.54%

6 Months

-32.53%

1 Year

-37.48%

2 Years

-28.47%

3 Years

-52.51%

4 Years

-64.62%

5 Years

-62.65%

DiaSorin SpA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-10.58%

EBIT Growth (5y)

-13.28%

EBIT to Interest (avg)

79.25

Debt to EBITDA (avg)

Net Debt to Equity (avg)

0.31

Sales to Capital Employed (avg)

0.12

Tax Ratio

32.92%

Dividend Payout Ratio

35.64%

Pledged Shares

Institutional Holding

0.01%

ROCE (avg)

48.00%

ROE (avg)

21.61%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.71

EV to EBIT

57.84

EV to EBITDA

47.96

EV to Capital Employed

2.27

EV to Sales

18.42

PEG Ratio

Dividend Yield

1.62%

ROCE (Latest)

3.92%

ROE (Latest)

6.73%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'16 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2016 is -100.00% vs 10.85% in Dec 2015",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2016 is -100.00% vs 25.00% in Dec 2015",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'16",
        "Dec'15",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "130.80",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.00",
          "val2": "49.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.90",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-2.40",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.00",
          "val2": "28.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "313.90%",
          "chgp": "-31.39%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 3.24% vs -15.64% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 18.04% vs -33.99% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,185.40",
          "val2": "1,148.20",
          "chgp": "3.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "406.70",
          "val2": "350.80",
          "chgp": "15.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "27.60",
          "val2": "29.40",
          "chgp": "-6.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.40",
          "val2": "-11.80",
          "chgp": "45.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "187.10",
          "val2": "158.50",
          "chgp": "18.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "234.20%",
          "val2": "205.40%",
          "chgp": "2.88%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'16 - YoY

Dec'16

Dec'15

Change(%)

Net Sales

0.00

130.80

-100.00%

Operating Profit (PBDIT) excl Other Income

0.00

49.30

-100.00%

Interest

0.00

0.90

-100.00%

Exceptional Items

0.00

-2.40

100.00%

Consolidate Net Profit

0.00

28.50

-100.00%

Operating Profit Margin (Excl OI)

0.00%

313.90%

-31.39%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2016 is -100.00% vs 10.85% in Dec 2015

Consolidated Net Profit

YoY Growth in quarter ended Dec 2016 is -100.00% vs 25.00% in Dec 2015

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

1,185.40

1,148.20

3.24%

Operating Profit (PBDIT) excl Other Income

406.70

350.80

15.94%

Interest

27.60

29.40

-6.12%

Exceptional Items

-6.40

-11.80

45.76%

Consolidate Net Profit

187.10

158.50

18.04%

Operating Profit Margin (Excl OI)

234.20%

205.40%

2.88%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 3.24% vs -15.64% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 18.04% vs -33.99% in Dec 2023

All Annual Results

Company CV

About DiaSorin SpA

DiaSorin SpA

Pharmaceuticals & Biotechnology

DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.

Company Coordinates

Company Details

Via Crescentino snc , SALUGGIA None : 13040

Tel: 39 0161 48752639 0161 487988

http://www.diasorin.com

Registrar Details